News | Women's Health | November 14, 2018

Merit Medical Completes Acquisition of Cianna Medical

Merit will continue to market Cianna’s wire-free breast localization products, including Scout and Savi Brachy technologies

Merit Medical Completes Acquisition of Cianna Medical

November 14, 2018 — Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to acquire Cianna Medical Inc., headquartered in Aliso Viejo, Calif. The deal structure includes an upfront payment of $135 million with potential earn-out payments of an additional $15 million for achievement of supply chain and scalability metrics, and up to an additional $50 million for achievement of sales milestones.

Cianna Medical develops, manufactures and markets products for wire-free breast localization, designed to reduce costs, improve quality, and reduce the anxiety and stress breast cancer treatments place on women and their families. Its research and development (R&D) and commercialization teams developed the first non-radioactive, wire-free breast localization system and what it calls the world’s only technology that utilizes radar in human tissue. Its Scout and Savi Brachy technologies are U.S. Food and Drug Administration (FDA)-cleared and address unmet needs in the delivery of radiation therapy, tumor localization and surgical guidance.

The Scout device has grown from $1 million in revenues in its 2015 debut to a projected $29 million in revenues in 2018. Current estimated market share is approximately 5 percent with no revenues currently outside the United States.

Merit Chairman and CEO Fred P. Lampropoulos said the Savi Scout is complementary to Merit’s strategic biopsy initiatives, noting that the product is pending CE mark approval in addition to its FDA clearance. Lampropoulos added that Merit intends to market the Savi Brachy, but only the catheter and not the radiation seeds.

For more information: www.ciannamedical.com, www.merit.com

Related Content

Single-slice of the chest CT showing the abnormalities. Arrows indicate the location of the breast mass (red arrow), lymphadenopathy (blue arrow), and a lung nodule (yellow arrow). Arrows not present in experimental display. Image courtesy of Psychonomic Bulletin & Review

Single-slice of the chest CT showing the abnormalities. Arrows indicate the location of the breast mass (red arrow), lymphadenopathy (blue arrow), and a lung nodule (yellow arrow). Arrows not present in experimental display. Image courtesy of Psychonomic Bulletin & Review

Feature | Radiology Imaging | November 20, 2020
There’s a classic video demonstrating how our brains process information and allocate attention in which people bounc
Ziehm Imaging will showcase its leading portfolio of mobile C-arms and advanced pre- and intraoperative image-based decision support solutions on its virtual RSNA 2020 booth
News | Mobile C-Arms | November 20, 2020
November 20, 2020 — Ziehm Imaging will showcase its leading portfolio of...
Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...